Foundation Medicine Inc (FMI) 23.73 $FMI
Foundation Medicine Announces Key Developments in International Commercialization Efforts
Business Wire - Mon May 12, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ: FMI) today announced that it has obtained a CE mark for FoundationOne(R). The CE mark allows FoundationOne to be placed on the market in the European Economic Area. In addition, Foundation Medicine has added to its growing global business partners by establishing a partnership with Barcelona, Spain-based Laboratorios LETI for the distribution of the company's clinical products to physicians in Spain and Portugal. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in select markets around the world.
Foundation Medicine Announces 2014 First Quarter Results and Recent Highlights
Business Wire - Wed May 07, 3:00PM CDT
Foundation Medicine, Inc. (NASDAQ: FMI) today reported total revenue of $11.5 million in the first quarter of 2014, compared to $9.7 million in the fourth quarter of 2013 and $5.2 million in the first quarter of 2013. Revenue from clinical testing in the first quarter was $7.1 million, which represents 34% growth in clinical revenue compared to the prior quarter. The company reported 4,702 clinical tests in the first quarter, up from 3,752 in the fourth quarter of 2013.
Foundation Medicine to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Tue May 06, 3:30PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Michael J. Pellini, M.D., president and chief executive officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13, 2014 at 1:40 p.m. P.T. in Las Vegas.
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
Foundation Medicine Announces Timing for First Quarter 2014 Financial Results and Conference Call
Business Wire - Wed Apr 16, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2014 will be released on Wednesday, May 7, 2014. The management team will host a conference call discussing the company's financial results and recent developments on Wednesday, May 7, 2014 at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 29386961.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Foundation Medicine Announces New Data Highlighting FoundationOne(TM) and FoundationOne(TM) Heme to be Presented at the AACR Annual Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new clinical data including additional validation for FoundationOne(TM) and FoundationOne(TM) Heme will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 taking place April 5-9, 2014 at the San Diego Convention Center.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
US Personalized Cancer Genome Sequencing Market Outlook 2018 Report Out Now
M2 - Tue Mar 18, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qp8lkm/us_personalized) has announced the addition of the "US Personalized Cancer Genome Sequencing Market Outlook 2018" report to their offering. The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing. The report entitled US Personalized Cancer Genome Sequencing Market Outlook 2018 entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018. The said advanced technology has potential to revolutionize the field of medicine. The author has closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, the author has also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual. Companies Mentioned: -Ambry Genetics -Beckman Coulter Genomics -BGI Americas Corporation -Cofactor Genomics -Complete Genomics -EdgeBio -Expression Analysis -Foundation Medicine -Illumina -SeqWright For more information visit http://www.researchandmarkets.com/research/qp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Foundation Medicine to Present at Upcoming Investor Conferences
Business Wire - Wed Feb 26, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
Foundation Medicine Announces 2013 Fourth Quarter and Year-End Results and Recent Highlights
Business Wire - Tue Feb 25, 3:01PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced total revenue of $9.7 million in the 2013 fourth quarter, compared to $8.2 million in the 2013 third quarter. The company reported 3,752 clinical tests in the 2013 fourth quarter, up from 2,577 in the 2013 third quarter. Total revenue for the year ended December 31, 2013 was $29.0 million, compared to $10.6 million for the prior year. More than 9,000 FoundationOne(TM) clinical tests were reported to physicians in 2013, up from 1,750 in 2012.
WIN Consortium Appoints Winston and Strawn LLP as Official Legal Counsel
Business Wire - Tue Feb 25, 5:00AM CST
The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine, www.winconsortium.org is proud to announce Winston and Strawn LLP (www.winston.com) has been appointed as their official legal advisor. WIN is a global network of leading academic, industry, payors and patient advocacy organizations working to make precision cancer care a reality for patients worldwide. WIN's goal is to significantly improve survival and quality of life of cancer patients in the next three years. Today WIN counts 32 members in 5 continents :
Foundation Medicine and Collaborators Identify High Incidence of Genomic Alterations Linked to Targeted Therapies in Liver Cancer; Data Published in The Oncologist
Business Wire - Mon Feb 24, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the results of a new study demonstrating that FoundationOne(TM) identified genomic alterations linked to targeted therapies or clinical trials in 71% (20/28) of patients with intrahepatic cholangiocarcinoma (ICC). ICC is a form of primary liver cancer that is rapidly increasing in incidence, typically associated with poor prognosis and often treated with systemic, non-targeted therapies extrapolated from treatments used in other gastrointestinal cancers. These results suggest that FoundationOne may be used to inform targeted treatment options for ICC patients based on the molecular profile of their tumor. The data were published in the current edition of The Oncologist.(1)
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call
Business Wire - Tue Feb 11, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released on Tuesday, February 25, 2014. The management team will host a conference call discussing the company's financial results and recent developments on Tuesday, February 25, 2014 at 4:30 p.m. ET. The call can be accessed by dialing 1-877-941-4774 (domestic) or 1-480-629-9760 (international) five minutes prior to the start of the call and providing the passcode 4667446.
2013 In-depth Study 'US Personalized Cancer Genome Sequencing Market' Discusses the Various Constraints
M2 - Mon Feb 10, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dksv5/us_personalized) has announced the addition of the "US Personalized Cancer Genome Sequencing Market" report to their offering. The US personalized cancer Genome Sequencing market is primarily classified into Targeted Genome Sequencing and Whole-Genome Sequencing. The report entitled US Personalized Cancer Genome Sequencing Market takes into account the Whole-Genome Sequencing services, which is one of the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment. In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome Sequencing market, our report has effectively studied the current and future status of cancer in the US as well as its States. In view of the fact that cancer affects some specific age groups in a significant manner, we have also investigated the age-wise statistics of the disease. To get proper insight into the market, an in-depth analysis into the high-income group population is provided so that players can have a clear picture about their potential customer base and the market to be tapped. The WGS industry has evolved in US in the recent times, and the level and seriousness of implementation has seen drastic changes. An in-depth study of the regulatory environment governing the US personalized cancer Whole-Genome Sequencing market has also been provided. It has been found that regulations related to personalized cancer sequencing are primarily governed with the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Further, the author has also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Companies Mentioned: - Ambry Genetics - Beckman Coulter Genomics - BGI Americas Corporation - Cofactor Genomics - Complete Genomics - EdgeBio - Expression Analysis - Foundation Medicine - Illumina - SeqWright For more information visit http://www.researchandmarkets.com/research/6d...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Foundation Medicine, Inc. [FMI] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Mon Feb 10, 9:00AM CST
What:
Foundation Medicine Announces Key Developments in International Commercialization Efforts
Business Wire - Mon May 12, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ: FMI) today announced that it has obtained a CE mark for FoundationOne(R). The CE mark allows FoundationOne to be placed on the market in the European Economic Area. In addition, Foundation Medicine has added to its growing global business partners by establishing a partnership with Barcelona, Spain-based Laboratorios LETI for the distribution of the company's clinical products to physicians in Spain and Portugal. The company anticipates this partnership will serve as a model for similar commercial relationships with leading distributors in select markets around the world.
Foundation Medicine Announces 2014 First Quarter Results and Recent Highlights
Business Wire - Wed May 07, 3:00PM CDT
Foundation Medicine, Inc. (NASDAQ: FMI) today reported total revenue of $11.5 million in the first quarter of 2014, compared to $9.7 million in the fourth quarter of 2013 and $5.2 million in the first quarter of 2013. Revenue from clinical testing in the first quarter was $7.1 million, which represents 34% growth in clinical revenue compared to the prior quarter. The company reported 4,702 clinical tests in the first quarter, up from 3,752 in the fourth quarter of 2013.
Foundation Medicine to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Tue May 06, 3:30PM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Michael J. Pellini, M.D., president and chief executive officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13, 2014 at 1:40 p.m. P.T. in Las Vegas.
Global & USA Cancer Biomarker Market Analysis 2014-2018
M2 - Thu May 01, 8:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6wrk6/global_and_usa) has announced the addition of the "Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)" report to their offering. GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Key Topics Covered: 1.0 Executive Summary 2.0 Global Burden of Cancer 3.0 Oncogenic Biomarkers - An Overview 4.0 Biomarker Validation 5.0 Current and Prospective Oncogenic Biomarkers 6.0 Cancer Biomarker Test Market Analysis 2013-2018 7.0 Oncology Biomarker Market Main Industry Players 8.0 Oncology Biomarker Market Products and Kits 9.0 Market Participant Financial and Business Strategy Analysis 10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market Companies Mentioned - 23andMe - Affymetrix - Ambry Genetics - Astex Pharmaceuticals - Atossa Genetics - BioMerieux - CuraGen - Celera Corporation (Quest Diagnostics) - Celldex Therapeutics - deCode Genetics (Amgen) - Foundation Medicine - Illumina - Genelex - Genomic Health - Myriad - Nodality - OriGene Technologies - Randox - Qiagen For more information visit http://www.researchandmarkets.com/research/j6...al_and_usa
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
Foundation Medicine Announces Timing for First Quarter 2014 Financial Results and Conference Call
Business Wire - Wed Apr 16, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2014 will be released on Wednesday, May 7, 2014. The management team will host a conference call discussing the company's financial results and recent developments on Wednesday, May 7, 2014 at 4:30 p.m. ET. The call can be accessed by dialing 1-855-420-0652 (domestic) or 1-484-365-2939 (international) five minutes prior to the start of the call and providing the passcode 29386961.
Upcoming Financial Results, Recent Investments and Agreements, and Expanded Collaborations - Analyst Notes on PerkinElmer, PAREXEL, WuXi, Response Genetics, and Foundation Medicine
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Foundation Medicine Announces New Data Highlighting FoundationOne(TM) and FoundationOne(TM) Heme to be Presented at the AACR Annual Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new clinical data including additional validation for FoundationOne(TM) and FoundationOne(TM) Heme will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 taking place April 5-9, 2014 at the San Diego Convention Center.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
US Personalized Cancer Genome Sequencing Market Outlook 2018 Report Out Now
M2 - Tue Mar 18, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qp8lkm/us_personalized) has announced the addition of the "US Personalized Cancer Genome Sequencing Market Outlook 2018" report to their offering. The whole genome sequencing technology, over the past decade, has developed at an unprecedented rate. There has been a rapid progression from targeted gene sequencing to targeted whole genome sequencing coupled with bioinformatics based sequencing platforms to analyze the data and thereby impart personalized treatment to individuals. The Whole Genome Sequencing has proved to be a key to new breakthrough in fighting against cancer. The explosion of genomic data into personalized treatment of cancer is due to the development of new methods, and the exponential decline in cost of whole genome sequencing. The report entitled US Personalized Cancer Genome Sequencing Market Outlook 2018 entails detailed study of current and future cancer prevalence and incidences across US. In addition, it provides an insight about the leading states with cancer incidences. Also covered is age wise statistics for cancer and comprehensive figures for cancer in males and females. Further, we have provided potential states for whole genome sequencing to help market players gauge maximum opportunity for growth. Besides, the report also provides potential customer base and the market's growth potential for personalized cancer WGS till 2018. The said advanced technology has potential to revolutionize the field of medicine. The author has closely monitored the regulatory landscape related to sequencing which requires consideration of the authorities over genome based tests. It has been observed that whole genome sequencing services have been concurrently regulated by FDA, CDC and CMS. Further, the author has also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Apart from this, a major hurdle is to persuade health insurers to reimburse for the cost of sequencing the genomes of individual. Companies Mentioned: -Ambry Genetics -Beckman Coulter Genomics -BGI Americas Corporation -Cofactor Genomics -Complete Genomics -EdgeBio -Expression Analysis -Foundation Medicine -Illumina -SeqWright For more information visit http://www.researchandmarkets.com/research/qp...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Foundation Medicine to Present at Upcoming Investor Conferences
Business Wire - Wed Feb 26, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
Foundation Medicine Announces 2013 Fourth Quarter and Year-End Results and Recent Highlights
Business Wire - Tue Feb 25, 3:01PM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced total revenue of $9.7 million in the 2013 fourth quarter, compared to $8.2 million in the 2013 third quarter. The company reported 3,752 clinical tests in the 2013 fourth quarter, up from 2,577 in the 2013 third quarter. Total revenue for the year ended December 31, 2013 was $29.0 million, compared to $10.6 million for the prior year. More than 9,000 FoundationOne(TM) clinical tests were reported to physicians in 2013, up from 1,750 in 2012.
WIN Consortium Appoints Winston and Strawn LLP as Official Legal Counsel
Business Wire - Tue Feb 25, 5:00AM CST
The Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine, www.winconsortium.org is proud to announce Winston and Strawn LLP (www.winston.com) has been appointed as their official legal advisor. WIN is a global network of leading academic, industry, payors and patient advocacy organizations working to make precision cancer care a reality for patients worldwide. WIN's goal is to significantly improve survival and quality of life of cancer patients in the next three years. Today WIN counts 32 members in 5 continents :
Foundation Medicine and Collaborators Identify High Incidence of Genomic Alterations Linked to Targeted Therapies in Liver Cancer; Data Published in The Oncologist
Business Wire - Mon Feb 24, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ: FMI) today announced the results of a new study demonstrating that FoundationOne(TM) identified genomic alterations linked to targeted therapies or clinical trials in 71% (20/28) of patients with intrahepatic cholangiocarcinoma (ICC). ICC is a form of primary liver cancer that is rapidly increasing in incidence, typically associated with poor prognosis and often treated with systemic, non-targeted therapies extrapolated from treatments used in other gastrointestinal cancers. These results suggest that FoundationOne may be used to inform targeted treatment options for ICC patients based on the molecular profile of their tumor. The data were published in the current edition of The Oncologist.(1)
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call
Business Wire - Tue Feb 11, 5:30AM CST
Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released on Tuesday, February 25, 2014. The management team will host a conference call discussing the company's financial results and recent developments on Tuesday, February 25, 2014 at 4:30 p.m. ET. The call can be accessed by dialing 1-877-941-4774 (domestic) or 1-480-629-9760 (international) five minutes prior to the start of the call and providing the passcode 4667446.
2013 In-depth Study 'US Personalized Cancer Genome Sequencing Market' Discusses the Various Constraints
M2 - Mon Feb 10, 10:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/6dksv5/us_personalized) has announced the addition of the "US Personalized Cancer Genome Sequencing Market" report to their offering. The US personalized cancer Genome Sequencing market is primarily classified into Targeted Genome Sequencing and Whole-Genome Sequencing. The report entitled US Personalized Cancer Genome Sequencing Market takes into account the Whole-Genome Sequencing services, which is one of the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment. In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome Sequencing market, our report has effectively studied the current and future status of cancer in the US as well as its States. In view of the fact that cancer affects some specific age groups in a significant manner, we have also investigated the age-wise statistics of the disease. To get proper insight into the market, an in-depth analysis into the high-income group population is provided so that players can have a clear picture about their potential customer base and the market to be tapped. The WGS industry has evolved in US in the recent times, and the level and seriousness of implementation has seen drastic changes. An in-depth study of the regulatory environment governing the US personalized cancer Whole-Genome Sequencing market has also been provided. It has been found that regulations related to personalized cancer sequencing are primarily governed with the accreditation of the laboratories performing the sequencing services and analysis, and also the usage of FDA approved tests for conducting these tests. Further, the author has also discussed the various constraints faced by the industry players with suitable suggestions to overcome them. Companies Mentioned: - Ambry Genetics - Beckman Coulter Genomics - BGI Americas Corporation - Cofactor Genomics - Complete Genomics - EdgeBio - Expression Analysis - Foundation Medicine - Illumina - SeqWright For more information visit http://www.researchandmarkets.com/research/6d...rsonalized About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Foundation Medicine, Inc. [FMI] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Mon Feb 10, 9:00AM CST
What:
